JP2016516721A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516721A5
JP2016516721A5 JP2016502966A JP2016502966A JP2016516721A5 JP 2016516721 A5 JP2016516721 A5 JP 2016516721A5 JP 2016502966 A JP2016502966 A JP 2016502966A JP 2016502966 A JP2016502966 A JP 2016502966A JP 2016516721 A5 JP2016516721 A5 JP 2016516721A5
Authority
JP
Japan
Prior art keywords
difficile
toxoid
toxin
formaldehyde
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016502966A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516721A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/029035 external-priority patent/WO2014144567A2/en
Publication of JP2016516721A publication Critical patent/JP2016516721A/ja
Publication of JP2016516721A5 publication Critical patent/JP2016516721A5/ja
Pending legal-status Critical Current

Links

JP2016502966A 2013-03-15 2014-03-14 トキソイド、組成物および関連方法 Pending JP2016516721A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790423P 2013-03-15 2013-03-15
US61/790,423 2013-03-15
PCT/US2014/029035 WO2014144567A2 (en) 2013-03-15 2014-03-14 Toxoid, compositions and related methods

Publications (2)

Publication Number Publication Date
JP2016516721A JP2016516721A (ja) 2016-06-09
JP2016516721A5 true JP2016516721A5 (https=) 2017-05-18

Family

ID=50489430

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502966A Pending JP2016516721A (ja) 2013-03-15 2014-03-14 トキソイド、組成物および関連方法

Country Status (13)

Country Link
US (2) US20160045586A1 (https=)
EP (1) EP2968507A2 (https=)
JP (1) JP2016516721A (https=)
KR (1) KR20150133770A (https=)
CN (1) CN105338997A (https=)
AR (1) AR095669A1 (https=)
AU (1) AU2014228956A1 (https=)
BR (1) BR112015023332A2 (https=)
CA (1) CA2907154A1 (https=)
HK (1) HK1213800A1 (https=)
SG (1) SG11201507608PA (https=)
TW (1) TWI624474B (https=)
WO (1) WO2014144567A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
JP6691477B2 (ja) * 2013-06-14 2020-04-28 サノフィ パストゥール インコーポレイテッド クロストリジウム・ディフィシル(c.difficile)に対して免疫する組成物及び方法
BR112017024443A2 (pt) * 2015-05-15 2018-10-23 Sanofi Pasteur Inc métodos para imunização contra clostridium difficile
US11154605B2 (en) 2017-06-09 2021-10-26 Hipra Scientific, S.L.U. Vaccine comprising Clostridium toxoids
US10096313B1 (en) * 2017-09-20 2018-10-09 Bose Corporation Parallel active noise reduction (ANR) and hear-through signal flow paths in acoustic devices
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
JP2024546686A (ja) * 2021-12-06 2024-12-26 ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー 癌を治療するための組成物及び方法
CN120615016A (zh) 2023-02-02 2025-09-09 葛兰素史克生物有限公司 免疫原性组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US5610023A (en) * 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
EP2305293A3 (en) * 1997-10-20 2013-11-06 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6669520B2 (en) 2001-09-19 2003-12-30 United Microelectronics Corp. Method of fabricating an LC panel
MX2010001054A (es) 2007-07-26 2010-04-21 Sanofi Pasteur Ltd Composiciones adyuvantes antigenicas y metodos.
HUE037932T2 (hu) 2007-09-14 2018-09-28 Sanofi Pasteur Biologics Llc Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók
GB201011968D0 (en) * 2010-07-16 2010-09-01 Secr Defence Toxoiding method

Similar Documents

Publication Publication Date Title
JP2016516721A5 (https=)
WO2021155243A8 (en) Respiratory virus immunizing compositions
PH12019501552A1 (en) Polypeptide-antigen conjugates with non-natural amino acids
PH12017501445A1 (en) Methods for producing virus for vaccine production
PH12018500856A1 (en) Respiratory syncytial virus vaccine
NZ622731A (en) Increasing virus-like particle yield in plants
PH12015500633A1 (en) Method for preparing imp fermented broth or glutamic acid fermented broth as raw material for preparation of natural flavor
CN106659777A8 (zh) 免疫原性组合产品
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
MX390947B (es) Composiciones terapéuticas de ceramidasa ácida y métodos para prepararlas y utilizarlas.
MY165831A (en) Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with a improved immunogenicity
MA32819B1 (fr) Vaccin combine notamment contre la coqueluche acellulaire
PH12015502217A1 (en) Influenza virus-like particle production in plants
PH12015501333B1 (en) Method of making a mycoplasma vaccine
WO2011043584A3 (ko) 형질전환 식물 유래의 고병원성 조류독감 바이러스 단백질 백신 및 그 제조방법
MX2020005554A (es) Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
PH12020550976A1 (en) Camp receptor protein variant and method of producing l-amino acid using the same
GEAP202415627A (en) Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same
MX385961B (es) Un método para la activación de bacterias de ácido láctico.
RU2017141773A (ru) Микроорганизм рода Escherichia, продуцирующий L-триптофан, и способ получения L-триптофана с его использованием
MX2021011913A (es) Composiciones de virus inactivado y formulaciones de vacunas contra el zika.
MX2024001304A (es) Composiciones y metodos para anticuerpos anti-pacap.
GEP20257808B (en) Immunogenic compositions against enteric diseases and methods for its preparation thereof
WO2023235660A3 (en) Flavivirus immunogens and vaccine compositions and methods of using the same
MX2017005080A (es) Preparacion de citrato de zinc y composiciones para cuidado oral que contienen citrato de zinc.